Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of 18-MC (Zolunicant) in Healthy Volunteers
NCT04292197Phase 1Completed
- Sponsor
- MindMed
- Start
- Apr 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 18-methoxycoronaridine in opioid use disorder (OUD) (4 arms), sponsored by MindMed. Primary endpoint: Incidence and Severity of Adverse Events up to 42 days. Started Apr 2020; status: completed.
02
Drugs
18-methoxycoronaridine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04292197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04292197.